Showing results (541-550 of 9,976) with videos related to

Sort By:
Pageof 998
Leukemia & Lymphoma|September 24, 2010
Energy metabolism of leukemia cells: glycolysis versus oxidative phosphorylationKazuto Suganuma, Hiroshi Miwa, Norikazu Imai, et al.
Leukemia & Lymphoma|December 8, 2010
Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimenSotirios Sachanas, Gerassimos A Pangalis, Theodoros P Vassilakopoulos, et al.
Leukemia & Lymphoma|December 8, 2010
A potential mechanism of rituximab-induced inhibition of tumor growth through its sensitization to tumor necrosis factor-related apoptosis-inducing ligand-expressing host cytotoxic cellsMario I Vega, Stavroula Baritaki, Sara Huerta-Yepez, et al.
Leukemia & Lymphoma|December 8, 2010
Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months)Christopher P Venner, Joseph M Connors, Heather J Sutherland, et al.
Leukemia & Lymphoma|December 8, 2010
Identification of new possible targets for leukemia treatment by kinase activity profilingArja Ter Elst, Sander H Diks, Kim R Kampen, et al.
Leukemia & Lymphoma|December 8, 2010
Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium WorkshopMichael E Williams, Joseph M Connors, Martin H Dreyling, et al.
Leukemia & Lymphoma|December 8, 2010
Molecular insight into the biology and clinical course of hairy cell leukemia utilizing immunoglobulin gene analysisFrancesco Forconi, Emanuele Cencini, Anna Sicuranza, et al.
Leukemia & Lymphoma|August 28, 2010
Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylationElizabeth A Griffiths, Steven D Gore, Craig Hooker, et al.
Leukemia & Lymphoma|August 28, 2010
Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisoneDavid Hui, Bradley Proctor, Jane Donaldson, et al.
Leukemia & Lymphoma|July 16, 2009
Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantationJayesh Mehta, Jayesh Mehta, Olga Frankfurt, et al.
Pageof 998